~5% of COVID-19 therapeutic candidates in clinical trials reached market

COVID-19 treatment pipeline

900 in preclinical development

680 in active clinical development
(20% repurposed)
(142 discontinued)

44 approved
(41% repurposed)
17 Approved in the U.S, U.K or E.U

7 WHO endorse

U.S./U.K./E.U. Approved:
Paxlovid (Full approval)
Remdesivir (Full approval)
Baricitinib (Full approval)
Tocilizumab (EUA)
Sarilumab (EUA)
Anakinra (EUA)
Dexamethasone (EUA)
Hydrocortisone (EUA)
LY-CoV555 mono-therapy (EUA)
REGEN-COV (EUA)
CT-P59 (EUA)
Sotrovimab (EUA)
Evvusheld (EUA)
LY-CoV1404 (EUA)
LY-CoV555 + LY-CoV16 combination (EUA)
Molnupiravir (EUA)
Ifax-1 (Vlobelimab) (EUA)

Nirmatrelvir+Ritonavir
Molnupiravir
Baricitinib
Remdesivir
Sarilumab
Tocilizumab
Dexamethasone

*Repurposed = candidate is approved for an alternate disease indication
Does not include phase IV clinical trials
62 COVID-19 vaccines have been approved; ~1 in 5 vaccines in clinical trials reached market

COVID-19 vaccines pipeline

494
in active preclinical development*

227
in active clinical development**
(89 inactive, rejected or discontinued)

62
approved
(14/62 variant updated)
15 approved in the U.S, U.K, E.U.

10
WHO endorsed

U.S./U.K./E.U. Approved:
mRNA-1273 (Moderna)
mRNA-1273.214 (Moderna)
mRNA-1273.222 (Moderna)
mRNA-1273.815 (Moderna)
BNT162b2 (Pfizer/BioNTech)
BA.1 bivalent vaccine (Pfizer/BioNTech)
BA.4/5 bivalent vaccine (Pfizer/BioNTech)
XBB.1.5 vaccine (Pfizer/BioNTech)

AZD1222 (AstraZeneca)
Ad26COV3 (J&J)
NVX-CoV2373 (Novavax)
Beta vaccine (Sanofi/GSK)
VLA2001 (Valneva/Dynavax)
GBP510 (SK Bioscience)
PPH-1V (HIPRA Scientific)

mRNA-1273 (Moderna)
BNT162b2 (Pfizer/BioNTech)
AZD1222 (AstraZeneca)
COVAXIN (Bharat)
Ad26COV3 (J&J)
CoronaVac (Sinovac)
NVX-CoV2373 (Novavax)
VLA2001 (Valneva/Dynavax)
Ad5-nCoV (Cansino)
BBIBP-CorV (Beijing/Sinopharm)

Pink = Variant updated

*Excludes inactive candidates
**Does not include phase IV clinical trials